Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

• Published in: Cells
• Main Authors: Ufuk Degirmenci, Mei Wang, Jiancheng Hu
• Format: Article
• Language: English
• Published: MDPI AG 2020-01-01
• Subjects: ras gtpases; raf family kinases; ras/raf/mek/erk signaling; braf(v600e); raf inhibitors; paradoxical activation; protein–protein interactions; synthetic lethal; neoplasm
• Online Access: https://www.mdpi.com/2073-4409/9/1/198

The RAS/RAF/MEK/ERK (MAPK) signaling cascade is essential for cell inter- and intra-cellular communication, which regulates fundamental cell functions such as growth, survival, and differentiation. The MAPK pathway also integrates signals from complex intracellular networks in performing cellular functions. Despite the initial discovery of the core elements of the MAPK pathways nearly four decades ago, additional findings continue to make a thorough understanding of the molecular mechanisms involved in the regulation of this pathway challenging. Considerable effort has been focused on the regulation of RAF, especially after the discovery of drug resistance and paradoxical activation upon inhibitor binding to the kinase. RAF activity is regulated by phosphorylation and conformation-dependent regulation, including auto-inhibition and dimerization. In this review, we summarize the recent major findings in the study of the RAS/RAF/MEK/ERK signaling cascade, particularly with respect to the impact on clinical cancer therapy.